XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Details Narrative)
12 Months Ended
Dec. 22, 2017
Dec. 31, 2018
USD ($)
Number
shares
Dec. 31, 2017
USD ($)
shares
Number of operating segment | Number   1  
Number of reporting unit | Number   1  
Depreciation expense | $   $ 1,706 $ 2,716
Impairment of goodwill | $   $ 1,246,002
Income tax rate 21.00% 23.90% 23.90%
Advance Pharmaceutical Company [Member] | Revenue [Member]      
Concentration risk   0.00% 25.00%
Royalty [Member]      
Revenue | $   $ 0 $ 7,380
Series A Preferred Stock [Member]      
Anti dilutive weighted average number of common shares   8,250,000 5,500,000
Stock Options [Member]      
Anti dilutive weighted average number of common shares   9,594,000 9,594,000
Warrant [Member]      
Anti dilutive weighted average number of common shares   38,999,990 41,029,669
Convertible Debt Securities [Member]      
Anti dilutive weighted average number of common shares   36,407,367 50,419,670